Latest Publications

Share:

Sandoz and Celltrion Decline the Invitation to Dance: Biosimilars Challenge the Applicability of the BPCIA’s Exchange Provisions...

In our blog post of November 18, 2013 (“No Avoiding BPCIA For Biosimilars: No Patent Declaratory Judgment Before Biosimilars Application is Filed”), we discussed the decision of the U.S. District Court for the Northern...more

11/13/2014 - Amgen Biosimilars BPCIA Declaratory Judgments FDA Patent Infringement Patent Litigation Patents Popular Public Health Service Act Sandoz

Supreme Court Hears Arguments on "Pay for Delay" Agreements

On March 25, 2012, the Supreme Court heard oral argument on the legality of “reverse payment” or “pay for delay” agreements between brand-name and generic drug manufacturers....more

4/5/2013 - FTC Generic Drugs Hatch-Waxman Patents Pay-For-Delay Reverse Payments SCOTUS

2 Results
|
View per page
Page: of 1